Danaher Corporation (ETR:DAP)
177.76
-0.24 (-0.13%)
May 13, 2025, 5:35 PM CET
Revenue by Product
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
---|---|---|---|---|---|
Period Ending | Mar '25 Mar 28, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Former Life Sciences | 14.11B |
Log In |
Log In |
Log In |
Log In |
Former Life Sciences Growth | 0.73% |
Log In |
Log In |
Log In |
Log In |
Diagnostics | 9.71B |
Log In |
Log In |
Log In |
Log In |
Diagnostics Growth | -0.20% |
Log In |
Log In |
Log In |
Log In |
Environmental & Applied Solutions | - |
Log In |
Log In |
Log In |
Log In |
Environmental & Applied Solutions Growth | - |
Log In |
Log In |
Log In |
Log In |
Biotechnology | 6.85B |
Log In |
Log In |
Log In |
Log In |
Biotechnology Growth | 0.22% |
Log In |
Log In |
Log In |
Log In |
Life Sciences | 7.26B |
Log In |
Log In |
Log In |
Log In |
Life Sciences Growth | 1.21% |
Log In |
Log In |
Log In |
Log In |
Recurring | 19.39B |
Log In |
Log In |
Log In |
Log In |
Recurring Growth | 3.04% |
Log In |
Log In |
Log In |
Log In |
Non-Recurring | 4.43B |
Log In |
Log In |
Log In |
Log In |
Non-Recurring Growth | -9.93% |
Log In |
Log In |
Log In |
Log In |
EBIT by Product
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
---|---|---|---|---|---|
Period Ending | Mar '25 Mar 28, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Former Life Sciences Operating Income | 2.65B |
Log In |
Log In |
Log In |
Log In |
Former Life Sciences Operating Income Growth | -4.17% |
Log In |
Log In |
Log In |
Log In |
Diagnostics Operating Income | 2.51B |
Log In |
Log In |
Log In |
Log In |
Diagnostics Operating Income Growth | -1.80% |
Log In |
Log In |
Log In |
Log In |
Environmental & Applied Solutions Operating Income | - |
Log In |
Log In |
Log In |
Log In |
Environmental & Applied Solutions Operating Income Growth | - |
Log In |
Log In |
Log In |
Log In |
Biotechnology Operating Income | 1.80B |
Log In |
Log In |
Log In |
Log In |
Biotechnology Operating Income Growth | 9.95% |
Log In |
Log In |
Log In |
Log In |
Life Sciences Operating Income | 845.00M |
Log In |
Log In |
Log In |
Log In |
Life Sciences Operating Income Growth | -24.76% |
Log In |
Log In |
Log In |
Log In |
Revenue by Geography
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
---|---|---|---|---|---|
Period Ending | Mar '25 Mar 28, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
North America | 10.25B |
Log In |
Log In |
Log In |
Log In |
North America Growth | 1.01% |
Log In |
Log In |
Log In |
Log In |
Western Europe | 5.48B |
Log In |
Log In |
Log In |
Log In |
Western Europe Growth | 2.16% |
Log In |
Log In |
Log In |
Log In |
Other Developed Markets | 1.23B |
Log In |
Log In |
Log In |
Log In |
Other Developed Markets Growth | -1.68% |
Log In |
Log In |
Log In |
Log In |
High-Growth Markets | 6870000000.00% |
Log In |
Log In |
Log In |
Log In |
High-Growth Markets Growth | -1.63% |
Log In |
Log In |
Log In |
Log In |
Other
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Core Sales Growth |
Log In |
Log In |
Log In |
Log In |
Core Sales Growth Ex-Cytiva |
Log In |
Log In |
Log In |
Log In |